CoChat

Nitric Oxide Production by Myeloid Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Open access

Published version of a preprint

The DOI matches its Crossref record; 58 of the 61 references it cites were found in a registry or an index, and 3 are not checked yet.

Abstract

Purpose: mAbs are used to treat solid and hematologic malignancies and work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated functions of NK cells from patients with cancer are significantly impaired. Identifying the mechanisms of this dysfunction and impaired response to mAb therapy could lead to combination therapies and enhance mAb therapy. Experimental Design: Cocultures of autologous NK cells and MDSC from patients with cancer were used to study the effect of myeloid-derived suppressor cells (MDSCs) on NK-cell FcR-mediated functions including antibody-dependent cellular cytotoxicity, cytokine production, and signal transduction in vitro. Mouse breast cancer models were utilized to study the effect of MDSCs on antibody therapy in vivo and test the efficacy of combination therapies including a mAb and an MDSC-targeting agent. Results: MDSCs from patients with cancer were found to significantly inhibit NK-cell FcR-mediated functions including antibody-dependent cellular cytotoxicity, cytokine production, and signal transduction in a contact-independent manner. In addition, adoptive transfer of MDSCs abolished the efficacy of mAb therapy in a mouse model of pancreatic cancer. Inhibition of iNOS restored NK-cell functions and signal transduction. Finally, nonspecific elimination of MDSCs or inhibition of iNOS in vivo significantly improved the efficacy of mAb therapy in a mouse model of breast cancer. Conclusions: MDSCs antagonize NK-cell FcR-mediated function and signal transduction leading to impaired response to mAb therapy in part through nitric oxide production. Thus, elimination of MDSCs or inhibition of nitric oxide production offers a strategy to improve mAb therapy. Clin Cancer Res; 24(8); 1891–904. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0691

Cites

58 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 275

Metadata

Authors
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., Landi, I., Hsu, V., Duggan, M., Wesolowski, R., Old, M., Howard, J. H., Yu, L., Stasik, N., Olencki, T., Muthusamy, N., Tridandapani, S., Byrd, J. C., Caligiuri, M., & Carson, W. E.
Affiliations
The Ohio State University (US)
Corresponding author
Carson, William E.
Venue
Clinical Cancer Research
Published
2018-04-12
Volume
24
Issue
8
Pages
1891-1904
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2806365158
Cited by
244
References
59
Citations by year
2026: 18 · 2025: 26 · 2024: 32 · 2023: 30 · 2022: 33 · 2021: 41 · 2020: 40 · 2019: 13 · 2018: 11
FWCI
11.28
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH (P01 CA95426, K24 CA93670, T32 CA90338-27, P30 CA016058)
  • OSUCCC (TT142)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
myeloid-derived suppressor cells, nitric oxide, inducible nitric oxide synthase, natural killer cells, Fc receptors, antibody-dependent cellular cytotoxicity, monoclonal antibody therapy, cancer immunotherapy resistance, breast cancer, pancreatic cancer, adoptive transfer, combination therapy
MeSH terms
Myeloid-Derived Suppressor Cells, Animals, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Cytotoxicity, Immunologic, Disease Models, Animal, Female, Humans, Killer Cells, Natural, Lymphocyte Activation, Neoplasms, Nitric Oxide, Receptors, Fc, Signal Transduction, Cytokines, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitric Oxide Production by Myeloid Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0691
The paper
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., Landi, I., Hsu, V., Duggan, M., Wesolowski, R., Old, M., Howard, J. H., Yu, L., Stasik, N., Olencki, T., . . . Carson, W. E. (2018). Nitric Oxide Production by Myeloid Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.